Technology
Biology Technology
Tigermed Sets Up Subsidiary, Hunan Tigermed Xiangya Drug R&D Ltd (Tigermed Xiangya)
| 12/1/2008 | HANGZHOU, China, Dec. 1 /PRNewswire-Asia/ -- Tigermed Consulting Co., Ltd,a leading Contract Research Organization (CRO) in China, announced that it hasestablished a subsidiary, Hunan Tigermed Xiangya Drug R&D Ltd, with Central South University (CSU). The establishment of Tigermed Xiangya marksTigermed's participation in the construction of a nationwide first-rate PhaseI Clinical... [Comments] |
| 12/1/2008 | FORT LAUDERDALE, Fla., Dec. 1 Imaging DiagnosticSystems, Inc., (OTC Bulletin Board: IMDS), a pioneer in laser optical breastimaging, announced today that a recent study on CTLM is one of the featuredscientific abstracts at RSNA 2008, November 30th - December 5th. Dr. Jin Qi,a radiologist at the Tianjin Medical University Cancer Institute and Hospital,Tianjin,... [Comments] |
Novavax CEO to Present at Piper Jaffray 20th Annual Healthcare Conference
| 12/1/2008 | ROCKVILLE, Md., Dec. 1 Novavax, Inc.(Nasdaq: NVAX ) a clinical-stage vaccine company, announced today that Dr.Rahul Singhvi, President and Chief Executive Officer, will be presenting atthe Piper Jaffray 20th Annual Healthcare Conference at 11:00 a.m. (EST) onDecember 2, 2008 in New York. Dr. Singhvi will provide an overview of thecompany's strategy, research... [Comments] |
PURE Bioscience and Ciba Strike New Contract for Natural Antimicrobial
| 12/1/2008 | Ciba to Accelerate Global Marketing of Ciba TINOSAN SDC in Personal Care, Household and Industrial Markets SAN DIEGO and BASEL, Switzerland, Dec. 1 PURE Bioscience (Nasdaq: PURE ) today announced it has signed a new agreement with Ciba (SWX: CIBN) to market and sell PURE's silver dihydrogen citrate antimicrobial as a preservative and biocide in the personal... [Comments] |
Ernst & Young Benchmarks Danish Biotech Pipeline Third in Europe
| 12/1/2008 | COPENHAGEN, December 1 A strong pipeline makes theCopenhagen Region biotech cluster well prepared for the challenges ahead.With 185 drug candidates in preclinical and clinical development, Denmarkranks third in Europe. Only United Kingdom and Germany have a bigger pipeline. Also in term of pipeline growth Denmark has a strong position as itexperienced the largest... [Comments] |
The Female Health Company Reports Record Results for Fiscal Year 2008, at High End of Guidance
| 12/1/2008 | CHICAGO, Dec. 1 The Female Health Company(Amex: FHC ), which manufactures and markets the FC Female Condom(R),today reported record operating results for the quarter and fiscal year endedSeptember 30, 2008. For the three months ended September 30, 2008, net revenues increased 52%to $7.8 million, compared with $5.2 million in the quarter ended Septembe... [Comments] |
Nuvelo and ARCA biopharma Advance Toward Completion of Merger
| 12/1/2008 | SAN CARLOS, Calif. and BROOMFIELD, Colo., Dec. 1 Nuvelo, Inc. (Nasdaq: NUVO ) and ARCA biopharma, Inc., a privately-heldbiopharmaceutical company developing genetically-targeted therapies for heartfailure and other cardiovascular diseases, today announced that a specialmeeting of Nuvelo's stockholders will take place on Wednesday, January 7 at 9a.m. PT at Nuv... [Comments] |
| 12/1/2008 | COLUMBIA, S.C., Dec. 1 Collexis Holdings, Inc.(OTC Bulletin Board: CLXS), a leading developer of semantic search andknowledge discovery software, announced today a partnership with BioFlorida,Inc., Florida's statewide bioscience association, to promote BiomedExperts.comto the association's 200+ membership base. Through the partnership,BiomedExperts.com will se... [Comments] |
| 12/1/2008 | BASKING RIDGE, N.J., Dec. 1 Regado Biosciences, Inc.,announced today David J. Mazzo, Ph.D., President and Chief Executive Officer,will present at the 20th Annual Piper Jaffray Health Care Conference in NewYork, NY, on Tuesday, December 2, 2008, at 10:10am (Eastern Standard Time).Dr. Mazzo will discuss the Company's development pipeline, in addition toreviewing recent bu... [Comments] |
| 12/1/2008 | CARLSBAD, Calif., Dec. 1 Isis Pharmaceuticals,Inc. (Nasdaq: ISIS ) announces the following webcast: What: New findings published in the journal Nature on the role of a microRNA, known as miR-21, in heart failure When: Monday, December 1, 2008, at 8:30 a.m. ET / 5:30 a.m. PT Where: http://www.isispharm.com How: Li... [Comments] |
| 12/1/2008 | -Calling for nomination of candidates worldwide - TOKYO, Dec. 1 The Science and Technology Foundation of Japan today announced the two fields eligible for the next Japan Prize, one of the world's most prestigious awards in science and technology. The 2010 Japan Prize will recognize outstanding achievements in industrial production and production technology and biologic... [Comments] |
Medicine Technology
Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics
| 12/1/2008 | PLYMOUTH MEETING, Pa., Dec. 1 Genaera Corporation (Nasdaq: GENR ) today announced that dosing of subjects has begun in study MSI-1436C-102 (Study 102), the multiple ascending dose Phase 1b study of trodusquemine (MSI-1436) in overweight and obese type 2 diabetics. MSI-1436 is a novel therapeutic for the treatment of type 2 diabetes and obesity which works centrally a... [Comments] |
| 12/1/2008 | KVISTGARD, Denmark, December 1 Following aRequest for Proposal issued in 2007 with the intent to procure an MVA-based,third generation smallpox vaccine, Public Works and Government ServicesCanada, on behalf of the Canadian Department of National Defence, has awardeda contract to Bavarian Nordic for the delivery of IMVAMUNE(R). The Canadian authoriti... [Comments] |
Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
| 12/1/2008 | -- Conference Call Scheduled for Tuesday, December 9 at 11:00 am ET to Discuss Phase 2 Study Results in AML -- SOUTH SAN FRANCISCO, Calif., Dec. 1 Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics, today announced new data from its studies of voreloxin... [Comments] |
GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America
| 12/1/2008 | ATLANTA, Dec. 1 GeoVax Labs, Inc.(OTC Bulletin Board: GOVX), an Atlanta-based biotechnology company developinghuman vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) andother infectious agents, announced today that the launch of its Phase 2a HumanVaccine Trials will take place in twelve sites across North and South America.These trials are c... [Comments] |
| 12/1/2008 | SAN DIEGO, Dec. 1 Vical Incorporated (Nasdaq: VICL ) announced today the receipt of a $1.0 million milestone payment from Merck & Co., Inc. based on Merck's planned initiation of a Phase I clinical trial of an investigational plasmid DNA (pDNA) cancer vaccine. The candidate vaccine is based on Vical's DNA gene delivery technology and encodes human telomerase rever... [Comments] |
Exercise Helps Prevent Age-Related Brain Changes in Older Adults
| 11/30/2008 | CHICAGO, Dec. 1 Older adults who exercise regularly show increased cerebral blood flow and a greater number of small blood vessels in the brain, according to findings presented today at the annual meeting of the Radiological Society of North America (RSNA). The study, conducted at the University of North Carolina ( UNC) - Chapel Hill , is the... [Comments] |
Brain Waves Show Sound Processing Abnormalities in Autistic Children
| 11/30/2008 | CHICAGO, Dec. 1 Abnormalities in auditory and language processing may be evaluated in children with autism spectrum disorder by using magnetoencephalography (MEG), according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA). "Using MEG, we can record the tiny magnetic fields associated with electrical brain... [Comments] |
German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008
| 11/28/2008 | GÿRLITZ, Germany, November 28 German biotech companyPartec is expanding its global leadership in specialized HIV monitoring andAIDS patient follow-up diagnostics for developing and emerging countries. Inthe year 2008, 2.5 million patient tests have been performed with theportable, robust and highly affordable "CyFlow" system, supporting alreadymore than 1 million p... [Comments] |
Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
| 11/28/2008 | INDIANAPOLIS, Nov. 28 Eli Lilly and Company(NYSE: LLY ) has withdrawn its supplemental New Drug Application (sNDA) fromthe U.S. Food and Drug Administration (FDA) for Cymbalta(R) (duloxetine HCl)for the management of chronic pain. Lilly plans to resubmit the application inthe first half of 2009, adding data from a recently completed positive studyin chronic... [Comments] |
St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse
| 11/27/2008 | New study finds the majority of acute lymphoblastic leukemia relapse cases arise from a cell already present at the time of diagnosis MEMPHIS, Tenn., Nov. 27 Scientists at St. Jude Children's Research Hospital have identified distinctive genetic changes in the cancer cells of children with acute lymphoblastic leukemia (ALL) that cause relapse. The finding of... [Comments] |
Eye Divergence in Children Triples Risk of Mental Illness
| 11/26/2008 | ROCHESTER, Minn., Nov. 26 Children whose eyes are misaligned and point outward are at significantly increased risk of developing mental illness by early adulthood, according to findings of a Mayo Clinic study published this month in Pediatrics , the official journal of the American Academy of Pediatrics. The retrospective study examined the medical records... [Comments] |
(Date:11/28/2008)...Newswire/ -- Why Humans Age is the title of an ...co-founder and formulator of Longevinex(R) (long-j...mote healthy aging. , , To view the Multim...ire.com/mnr/longevinex/35829/ , , The film...ng -- that humans begin to age biologically only a...
(Date:11/27/2008)...can Ancestry Helps A-List Line Up of African Ameri...rica; RIse of consumer genetic testing coupled wit...rend in African Americans to trace roots to Africa... Washington, DC (PRWEB) November 27,...n,t have to grapple with in the Oval Office is his...
(Date:11/26/2008)...fiction writers have long envisioned sailing a spa...ut, the forces of sunlight are too weak to fill ev... team led by researchers at the Yale School of En...rce of light indeed can be harnessed to drive mach...ns. , Their work opens the door to a new class ...
(Date:11/26/2008)...new DNA Mini Portrait™ is this years, most u...w York, NY(PRWEB) November 26, 2008 --DNA 11, the ...rom the customers, DNA, launch DNA Mini Portraits&...bines art, technology, beauty and pop culture. DN...olution for this holiday season that are being unv...
Breaking Biology Technology:Video: 8-Minute Film Documentary Explores Why Humans Age 2Growing Interest in DNA-Based Genetic Testing Among African American with Historic Election of President Elect Barack Obama 2Growing Interest in DNA-Based Genetic Testing Among African American with Historic Election of President Elect Barack Obama 3'The photon force is with us': Harnessing light to drive nanomachines 2DNA 11, Creators of DNA Art, Introduces a More Affordable Line of Custom Portraits for this Year's Gift Giving Season 2[0] Video: 8-Minute Film Documentary Explores Why Humans Age[1] Growing Interest in DNA-Based Genetic Testing Among African American with Historic Election of President Elect Barack Obama [0] 'The photon force is with us': Harnessing light to drive nanomachines[0] DNA 11, Creators of DNA Art, Introduces a More Affordable Line of Custom Portraits for this Year's Gift Giving Season
... The DELFIA time-resolved fluorescence assay fo... is a 96-well microplate assay that measures the i...nylated nicotinamide adenine diphsophate (NAD). Th... streptavidin. The method is a convenient way to s...oughput primary screening and secondary screening....
... , Introduction , A phosph... an accessory on the SPEX FLUOROLOG system can...of chemical and biochemical interest, by revealing...cence. , <P,>This Application Note descri...f energy-transfer from a peptide-terbium-complex d...
... , Introduction , The chem...gen, 1 O 2 , is of considerable interest in envir... mechanisms of photo-oxygenation. 1 Recently, res...biological effects of 1 O 2 , such as the photody...e, oxygen, and light. <P,>An understanding of th...
... , Introduction , Protein-...countries. The ability to produce enough crops is ...eople have to have enough to eat before they can a...ollable changes in weather such as the amount of r...c., can be detrimental to the success of a harvest...
Other Biology Technology:A DELFIA Assay for Inhibition of PARP 2A DELFIA Assay for Inhibition of PARP 3Phosphorescence lifetime measured using the SPEX phosphorimeter 2Singlet Oxygen measurement 2Food science: increasing crop yields 2(Date:11/25/2008)...n Clinical Trial to Assess Survival of Patients Re... Unresectable Hepatocellular Carcinoma , , ...ences Oncology, Inc. (LSO) today announced the com... trial of Light Infusion Therapy(TM) (Litx(TM)) as...noma (HCC), also known as hepatoma or primary live...
(Date:11/24/2008)...AKA, Japan, Nov. 24 Takeda Pharmac...diary, Takeda Global Research & Development Ce...is Advisory Committee of the U.S. Food and Drug Ad...e febuxostat for the treatment of hyperuricemia i...avor of approval, with one panel member abstaining...
(Date:11/24/2008)...24 Leaders of Schering-P... update for investors on the company,s research pi...io that includes 46 new entities in clinical trial... studies. , , "Research and development is ...we continue our transformation," said Fred Hassan,...
(Date:11/24/2008)...nnovation leadership and long-term commitment to h.... 24 Schering-Plough Cor...update on boceprevir, its lead investigational ora...e III development. The company believes boceprevi...t-in-class protease inhibitor for treating chronic...
Breaking Medicine Technology:Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 2Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 2Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 2Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 4Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 6Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 7Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 8Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 9Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at th 2163 1Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at th 2163 2Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at th 2163 3Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at th 2163 4Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at th 2163 5Aflac to be Primary Sponsor of Carl Edwards and the No 99 Ford Fusion 19987 1Aflac to be Primary Sponsor of Carl Edwards and the No 99 Ford Fusion 19987 2Aflac to be Primary Sponsor of Carl Edwards and the No 99 Ford Fusion 19987 3Agito Networks Wins Red Herring North America 100 Award Out of More Than 800 Companies 19985 1Agito Networks Wins Red Herring North America 100 Award Out of More Than 800 Companies 19985 2Agito Networks Wins Red Herring North America 100 Award Out of More Than 800 Companies 19985 3Health WorldNet Inc Launches New Web Portal for Health 26 Medical Resources 19983 1Health WorldNet Inc Launches New Web Portal for Health 26 Medical Resources 19983 2[0] Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma[0] Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout[2] Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects[0] Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
...reatment with Copaxone Plus Minocycline Showed Sub... with Active,Relapsing-Remitting Multiple Sclerosi...Reduced Brain,Lesions and Was Well Tolerated , KAN...ized,double-blind study showed that a combination...with the oral antibiotic,minocycline reduced T1 Ga...
...AMBRIDGE, England, 4th May 2007 - CeNeS Pharmaceut...aceutical company, notes,the publication of an ind... ,Synapse,* on its Phase II NMDA antagonist, CNS 5...reatment for neuropathic,pain. The independent stu...taken with CNS 5161. , In the study reported in ,S...
Other Medicine Technology:Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 2Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 4Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 5Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 6Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 7Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 8Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 9Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 10Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 11Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 12Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 2Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 3| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |